Progestin-Primed Ovarian Stimulation with Dydrogesterone Versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in Vitro Fertilization: A Retrospective Cohort Study

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2020 Feb 27

PMID 32099323

Citations 9

Authors

Jialyu Huang

Qin Xie

Jiaying Lin

Xuefeng Lu

Jing Zhu

Hongyuan Gao

Renfei Cai

Yanping Kuang

Affiliations

Soon will be listed here.

Abstract

Purpose: Dydrogesterone (DYG) is an alternative progestin in progestin-primed ovarian stimulation (PPOS) protocol with weaker pituitary suppression than medroxyprogesterone acetate (MPA) in normal ovulatory women. However, the endocrinological characteristics, oocyte retrieval and pregnancy outcomes of DYG application in polycystic ovarian syndrome (PCOS) patients undergoing in vitro fertilization (IVF) remain unclear.

Patients And Methods: This retrospective cohort study included 420 PCOS patients who underwent controlled ovarian stimulation with human menopausal gonadotropin (hMG) and DYG (n=105) or MPA (n=315) from January 2014 to December 2017. Baseline characteristics of the two groups were balanced with propensity score matching using the nearest-neighbor random matching algorithm in a ratio of 1:3. The primary outcome measure was the number of oocytes retrieved. Other main outcome measures included the number of viable embryos, incidence of premature luteinizing hormone (LH) surge and live birth rate per frozen-thawed embryo transfer (FET) cycle.

Results: A similar number of oocytes was retrieved in the two protocols (16.1±6.5 vs 15.1±10.0, =0.342). Patients in both groups achieved consistent LH suppression with no premature LH surge detected. In the DYG + hMG group, the mean LH levels were significantly higher than the MPA + hMG group on cycle day 9-11 and trigger day (all <0.001), and the dose of hMG was significantly lower (1710.7±431.6 vs 1891.3±402.2 IU, <0.001). No significant between-group differences were found in the number of viable embryos (5.3±3.1 vs 5.0±4.1, =0.139) and live birth rate per FET cycle (43.5% vs 47.7%, =0.383). None of the participants experienced moderate-to-severe ovarian hyperstimulation syndrome in either group.

Conclusion: Our results showed that the application of DYG in PPOS protocol could achieve comparable oocyte retrieval and pregnancy outcomes to MPA, but significantly reduce the consumption of gonadotropins in PCOS women for IVF treatment.

Citing Articles

A multicycle approach through DuoStim with a progestin-primed ovarian stimulation (PPOS) protocol: a valuable option in poor prognosis patients undergoing PGT-A.

Vaiarelli A, Pittana E, Cimadomo D, Ruffa A, Colamaria S, Argento C J Assist Reprod Genet. 2024; 42(1):255-264.

PMID: 39538089 PMC: 11805732. DOI: 10.1007/s10815-024-03317-0.

Effect of medroxyprogesterone acetate dose in progestin-primed ovarian stimulation on pregnancy outcomes in poor ovarian response patients with different body mass index levels.

Zhang Q, He S, Meng Y, Yin T, Ming L, Yang J Front Endocrinol (Lausanne). 2024; 15:1352522.

PMID: 38699386 PMC: 11063298. DOI: 10.3389/fendo.2024.1352522.

The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: a propensity score-matched study.

Zhang Y, Li H, Zhu S, Jiang S, Zhao W, Wang X Front Endocrinol (Lausanne). 2023; 14:1295787.

PMID: 38155955 PMC: 10754509. DOI: 10.3389/fendo.2023.1295787.

Comparison of Cumulative Live Birth Rates between Flexible and Conventional Progestin-Primed Ovarian Stimulation Protocol in Poor Ovarian Response Patients According to POSEIDON Criteria: A Cohort Study.

Chen Y, Chu Y, Yao W, Wang L, Zeng W, Yue J J Clin Med. 2023; 12(18).

PMID: 37762716 PMC: 10531846. DOI: 10.3390/jcm12185775.

Effect of acarbose combined with diet intervention on glycolipid metabolism in patients with primary polycystic ovarian syndrome complicated with impaired glucose tolerance.

Yang Q, Zhang W, Zhang J, Niu S Pak J Med Sci. 2022; 38(4Part-II):992-997.

PMID: 35634619 PMC: 9121947. DOI: 10.12669/pjms.38.4.4598.

References

Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y . Transfer of Fresh versus Frozen Embryos in Ovulatory Women. N Engl J Med. 2018; 378(2):126-136. DOI: 10.1056/NEJMoa1705334. View

Yu S, Long H, Chang H, Liu Y, Gao H, Zhu J . New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018; 33(2):229-237. DOI: 10.1093/humrep/dex367. View

Sturmer T, Joshi M, Glynn R, Avorn J, Rothman K, Schneeweiss S . A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006; 59(5):437-47. PMC: 1448214. DOI: 10.1016/j.jclinepi.2005.07.004. View

Sterling L, Liu J, Okun N, Sakhuja A, Sierra S, Greenblatt E . Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril. 2015; 105(3):791-797.e2. DOI: 10.1016/j.fertnstert.2015.11.019. View

Di Paola R, Garzon S, Giuliani S, Lagana A, Noventa M, Parissone F . Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve. Arch Gynecol Obstet. 2018; 298(5):1029-1035. DOI: 10.1007/s00404-018-4906-2. View

Azziz R, Carmina E, Chen Z, Dunaif A, Laven J, Legro R . Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057. DOI: 10.1038/nrdp.2016.57. View

Fischer D, Reisenbuchler C, Rosner S, Haussmann J, Wimberger P, Goeckenjan M . Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS. Geburtshilfe Frauenheilkd. 2016; 76(6):718-726. PMC: 4922889. DOI: 10.1055/s-0042-100206. View

Bosch E, Valencia I, Escudero E, Crespo J, Simon C, Remohi J . Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003; 80(6):1444-9. DOI: 10.1016/j.fertnstert.2003.07.002. View

Wildt L, Hutchison J, Marshall G, Pohl C, Knobil E . On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. Endocrinology. 1981; 109(4):1293-4. DOI: 10.1210/endo-109-4-1293. View

10.

Larue L, Keromnes G, Massari A, Roche C, Moulin J, Gronier H . Transvaginal ultrasound-guided embryo transfer in IVF. J Gynecol Obstet Hum Reprod. 2017; 46(5):411-416. DOI: 10.1016/j.jogoh.2017.02.015. View

11.

Zhang J, Mao X, Wang Y, Chen Q, Lu X, Hong Q . Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet. 2017; 296(6):1207-1217. DOI: 10.1007/s00404-017-4537-z. View

12.

. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016; 106(7):1634-1647. DOI: 10.1016/j.fertnstert.2016.08.048. View

13.

Harris T, Dye S, Robinson J, Skinner D, Evans N . Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropin-releasing hormone surge-generating system. Endocrinology. 1999; 140(2):827-34. DOI: 10.1210/endo.140.2.6490. View

14.

Cummins J, Breen T, Harrison K, Shaw J, Wilson L, Hennessey J . A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transf. 1986; 3(5):284-95. DOI: 10.1007/BF01133388. View

15.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

16.

Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H . Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13:2553-2563. PMC: 6667350. DOI: 10.2147/DDDT.S210228. View

17.

Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q . Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015; 104(1):62-70.e3. DOI: 10.1016/j.fertnstert.2015.03.022. View

18.

Mourad S, Brown J, Farquhar C . Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017; 1:CD012103. PMC: 6469542. DOI: 10.1002/14651858.CD012103.pub2. View

19.

Chen H, Wang Y, Lyu Q, Ai A, Fu Y, Tian H . Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015; 103(5):1194-1201.e2. DOI: 10.1016/j.fertnstert.2015.02.020. View

20.

Tournaye H, Sukhikh G, Kahler E, Griesinger G . A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5):1019-1027. PMC: 5400051. DOI: 10.1093/humrep/dex023. View